

www.jmscr.igmpublication.org

Impact Factor 3.79

ISSN (e)-2347-176x

crossref DOI: <http://dx.doi.org/10.18535/jmscr/v3i8.54>



Journal Of Medical Science And Clinical Research

An Official Publication Of IGM Publication

Role of Dexmedetomidine on Hemodynamics and Anesthetic Requirement During Elective Intracranial Tumor Surgery - A Prospective Randomized Double Blind Placebo Controlled Study

Authors

***Amrita Roy¹, Suman Sarkar², Sankari Santra³, Anusua Banerjee⁴, Shanta Ganguly⁵**

^{1,3,5}Dept. of Anesthesiology, I.P.G.M.E&R and SSKM Hospital. 244 A.J.C Bose Road, Kolkata, PIN – 700020, India

Email Id: royamrita002@gmail.com, sankarisantra@yahoo.com, gangulyshanta@rediffmail.com

²Dept. of Pediatrics, I.P.G.M.E&R and SSKM Hospital. 244 A.J.C Bose Road, Kolkata, PIN – 700020, India

Email: dr.sumansarkar@gmail.com

⁴Dept. of Cardiac Anesthesiology, I.P.G.M.E&R and SSKM Hospital 244 A.J.C Bose Road, Kolkata, PIN – 700020, India

Department of Anesthesiology, I.P.G.M.E&R, 244 A.J.C Bose Road, Kolkata, PIN – 700020, India

Corresponding Author

Dr. Amrita Roy

M.D, RMO cum Clinical Tutor, Dept. of Anesthesiology, I.P.G.M.E&R and SSKM Hospital

Email Id: royamrita002@gmail.com, Phone no. +919432310162

Abstract

Background: The objective of present study was to compare the effects of dexmedetomidine with placebo on intraoperative hemodynamics and anesthetic requirements during intracranial tumor surgery.

Methods: Ninety patients of ASA physical status 1 or 2, scheduled for elective intracranial tumor surgery, were allocated into group D and group C each consisting of 45 patients. Group D received dexmedetomidine 1 µg/kg over 10 minutes followed by maintenance infusion 0.4µg/kg/hr which was discontinued at skin closure. Group C received normal saline in a similar manner. Anesthesia was induced after 20 minutes of starting the maintenance infusion with propofol and maintained with nitrous oxide in oxygen, continuous infusion of propofol, atracurium and intermittent fentanyl. Heart rate, systolic, diastolic and mean blood pressures were recorded and compared. The requirements of propofol and fentanyl in both groups were also compared.

Results: Dexmedetomidine significantly attenuated hemodynamic response at intubation, head pin fixation, skin incision, making of burr hole, opening of dura and at extubation ($p < 0.001$). Total dose of propofol as well as induction and maintenance dose requirement were significantly lower in group D ($p < 0.0001$). Total and hourly fentanyl requirement was also less in group D ($p < 0.0001$). Patients in group D were extubated earlier than patients in group C ($p < 0.0001$). Group D patients required less postoperative analgesic ($p < 0.026$).

Conclusion: Dexmedetomidine attenuated the hemodynamic response significantly, maintained perioperative hemodynamic stability, decreased extubation time as well as reduced intraoperative propofol and fentanyl and postoperative analgesic requirement in intracranial tumor surgery.

Key words: Dexmedetomidine, Propofol, Fentanyl, hemodynamics, Intracranial tumor surgery

Introduction

The goals of neuroanesthesia are to maintain a stable cerebral hemodynamics and a good operating condition without sudden increase in brain volume and intracranial pressure. Rapid recovery from anesthesia is also required for early neurological evaluation. As the autoregulation is impaired in tumor region, sudden increase in arterial blood pressure is associated with intracranial bleeds and edema formation^[1]. It may increase the morbidity and prolong hospital stay. Thus prevention and control of hemodynamic responses to varying degree of nociceptive stimuli at critical moments of anesthesia and surgery (e.g., laryngoscopy and endotracheal intubation, head pin fixation, skin incision, traction on pain sensitive structures, extubation) are of utmost importance to preserve cerebral homeostasis in neurosurgical patients. Routinely different anesthetic agents and antihypertensive medicines are used to maintain the stable hemodynamics. But they may take time to control hypertension followed by a subsequent period of hypotension or there may be delayed recovery from anesthesia.

Dexmedetomidine, an α -2 adrenoreceptor agonist has recently been introduced in neuroanesthesia practice, because of its sympatholytic, sedative and hemodynamic stabilizing properties^[2,3]. It is 16 times more potent than clonidine and having analgesic effects without significant respiratory depression^[4]. Dexmedetomidine also reduces the need for opioid and anesthetic requirement and a potentially useful anesthetic adjuvant for neurosurgical cases^[5].

This study was designed to assess the efficacy of dexmedetomidine in controlling hypertensive response in patients undergoing intracranial tumor surgery under general anesthesia. Intraoperative anesthetic requirements were also noted as secondary outcome.

Materials and Methods

After obtaining approval from Institutional Ethics Committee, 90 patients aged 18-65 years, of either sex, of ASA status 1 or 2, with Glasgow Coma Scale of 14 or 15 and scheduled to undergo

elective craniotomy for supratentorial tumor were enrolled in this study. The exclusion criteria were as follows: pregnant or nursing woman, morbid obesity, preoperative heart rate < 45 beats/min, second or third degree heart block, medication with beta blocker, α methyl dopa, clonidine, or other α 2 agonists, psychiatric diseases, renal and hepatic diseases.

Balanced randomization using permuted blocks was applied. The patients were randomized into two groups consisting of 45 patients in each group. Routine medications were continued as clinically applicable. Two hours before transferring the patient to the operating room, all puncture sites were treated with topical anesthetic cream. On arrival to operating room, a central venous line in subclavian vein and a radial arterial cannulation were done under local anesthesia for central venous and arterial pressure monitoring as well as for blood sampling. Drug was prepared and administered by one anesthesiologist who was completely unaware of the study objectives and data was collected by investigator. Group D, the Dexmedetomidine group received Dexmedetomidine 1 μ g/kg over 10 minutes followed by a maintenance infusion of 0.4 μ g/kg/hr. Induction of anesthesia was done after 20 min of starting the maintenance infusion. It was discontinued at skin closure. Dexmedetomidine was supplied in 2-mL ampoules of 100 μ g/ml concentration, and this volume was diluted with 198 mL of normal saline to yield a final concentration of 1 μ g/ml. Group C, the placebo group received similar volumes of saline in similar manner. In both groups the bolus started 30 min before induction. All patients were preoxygenated, and then induced with intravenous Propofol (1-2 mg/kg) and Fentanyl (2 μ g/kg). Tracheal intubation was facilitated with Atracurium 0.5 mg/kg as a bolus dose over 30 sec. Patients were moderately hyperventilated with Oxygen / Nitrous oxide (1:1) and was adjusted to maintain PaCO₂ between 30 and 35 mmHg.

The anesthesia was maintained with Propofol and Atracurium infusion. Atracurium was administered by intravenous infusion at a rate of 0.5 mg/kg/hr and. Bolus doses of Fentanyl (1 μ g/kg)

were administered before head pin fixation. Propofol infusion was titrated to maintain a Bispectral index (BIS) of 40-60. Mannitol (1 gm/kg) was administered to every patient during the first burr hole. Dexmedetomidine or placebo infusions were stopped at starting of skin closure. Fluids for resuscitation and maintenance were provided with glucose free iso-osmolar crystalloid solutions 2-3 ml/kg/hr, and replacement of blood loss was done as per standard guideline. Urine output was monitored. All patients received Ondansetron 4 mg and underwent routine reversal of neuromuscular blockade. Patients were awakened and extubated in the operating room and transferred to postanesthesia care unit after following simple commands.

Hemodynamic events that required treatment were defined as hypotension – Systolic blood pressure (SBP) < 90 mm Hg, hypertension - SBP > 180 mm Hg or diastolic blood pressure (DBP) > 105 mm Hg or mean arterial pressure (MAP) >130 mm Hg, bradycardia – heart rate (HR) <50 beats/minute, and tachycardia - HR >100 beats/min.

Hypertension and or tachycardia in spite of maintaining BIS 60 were managed with bolus i.v fentanyl 1-2 µg/kg. If not corrected then incremental doses of labetalol 10 mg was administered. Hypotension was managed with fluid and an incremental dose of phenylephrine 50 µg. Bradycardia with hemodynamic instability was treated with 0.6 mg i.v atropine.

The data of patients was collected by the investigator at the following time points – baseline (T0), after bolus dose (T1), at induction (T2), intubation (T3), head pin fixation (T4), skin incision (T5), making of burr hole (T6), opening of dura (T7) and extubation (T8).

The numbers of interventions done when hemodynamic variables were outside the predetermined window were recorded.

Statistical analysis

Data were expressed as mean ± standard deviation (SD) for continuous normally distributed variables, median and interquartile range for non-

normally distributed data, and proportion or counts for categorical data. All statistical tests were done using computer programs Microsoft Excel spreadsheet version 2007 (Microsoft Corporation, New York, USA) and XLSTAT version 2015.4.01.20780 (Adinsoft) statistical program for Microsoft Windows. All tests were two tailed and p value less than 0.05 were considered statistically significant. Continuous data between groups were analyzed using Student's t test or Mann Whitney U test depending on the normality of the data. Continuous data within a single group across various time points were analyzed using Friedman's Analysis of Variance followed by Wilcoxon's matched pair signed rank test post hoc analysis. Dichotomous data were analyzed using Pearson's chi square test or Fisher's exact test as applicable.

Results

After applying the inclusion and exclusion criteria, ninety patients, aged between 18-65 yrs, ASA grade I and II, scheduled to undergo intracranial tumor surgery, were studied.

The demographic characteristics were comparable in both groups [Table 1].

The time from induction of anesthesia to extubation was 275.82±24.25 minutes and 275.56±22.63 minutes in group D and group C respectively and it was comparable (p 0.957) [Figure 1].

Increase in heart rate was attenuated better in group D (P <0.05) during specific time points which are known to cause considerable hemodynamic alterations, i.e after loading dose of dexmedetomidine (p 0.001), at the time of induction (p 0.00), laryngoscopy and intubation (p 0.001), head pin fixation (p 0.001), skin incision (p 0.001), making of burr hole (p 0.001), opening of dura (p 0.001) and extubation (p 0.001) [Table 2].

Attenuation in systolic blood pressure, diastolic blood pressure, mean blood pressure were statistically significant throughout the intraoperative period (p 0.00) [Table 3, 4, 5].

The mean induction dose of propofol was 5.62 ± 1.45 mL and 10.56 ± 1.4 mL in group D and C respectively ($p < 0.0001$). Total and hourly mean maintenance requirement of propofol in both groups were 41.38 ± 9.16 mL and 8.28 ± 1.83 mL in group D and 132.89 ± 20.43 mL and 28.12 ± 3.72 mL in group C ($p < 0.0001$). Total and hourly requirement of fentanyl was significantly lower in group D ($p < 0.0001$) [Table 6, 7].

It was found that total seven (15%) patients suffered from tachycardia in group D whereas it was 28 patients (62%) in group C ($p < 0.001$). Use of Esmolol was significantly lower in group D ($p < 0.0001$). Bradycardia occurred in 14 patients and 12 patients in group D and group C respectively ($p 0.897$). Four (4 patients, 8.8%) patients in group D received intravenous atropine to combat unstable bradycardia while it was three (3 patients, 7.14%) ($p 0.925$) [Table 8]. No significant difference in occurrence of both intraoperative hypertension and hypotension was found ($p 0.169$, $p 0.94$ respectively). Every cases of hypotension received medical intervention as per protocol. There was no difference in administration of phenylephrine ($p 0.7$). Intravenous labetalol was used to treat hypertension only in 4 patients in group D, whereas it was administered in 12 patients in group C ($p 0.015$). No patient in group D whereas 5 patients suffered from hypertension at extubation ($p 0.07$). No significant difference in occurrence of postoperative nausea vomiting and shivering was present ($p 1.00$, $p 0.07$ respectively).

Tracheal extubation was faster in group D (mean 16.58 ± 4.9 min) than group C (mean 33.6 ± 7.5 min) ($p < 0.0001$). Arterial CO_2 tension was maintained in the range of 30-35 mm Hg in both groups. After extubation every patient was fully conscious, well oriented and maintained SpO_2 in the range of 95-100%. Supplemental O_2 40% via face mask was provided to every patient postoperatively. Only two patients required analgesic in the immediate postoperative period in group D, whereas 11 patients in group C required

the same ($p 0.026$). Every patient was shifted to neuro ICU after extubation.

Discussion

We conducted the prospective randomized double blind placebo controlled study to examine whether addition of dexmedetomidine to a commonly administered balanced anesthetic regimen improves hemodynamics or not in patients undergoing elective craniotomy. The study demonstrated that, addition of continuous infusion of dexmedetomidine attenuated the hemodynamic responses at critical moments of anesthesia and surgery. As a secondary outcome measure, reduced intraoperative propofol and fentanyl requirement was noted.

Dexmedetomidine is a highly selective α -2 adrenoceptor agonist that has been shown to have sedative, analgesic and anesthetic sparing effects ^[4,6,7,8,9]. It causes dose dependant decrease in arterial blood pressure and heart rate associated with a decrease in serum nor-epinephrine concentration ^[10]. Among other major advantages, it's faster onset of action and shorter half life allow effective titration of drug dose.

The concept of neuroanesthesia includes several principals, the hemodynamic stability being most important. There are many causes responsible for hypertension during craniotomy. The final common pathway leading to perioperative hypertension appears to be activation of the sympathetic nervous system, as evidenced by increased plasma catecholamine concentration in patients after craniotomy ^[11]. A number of antihypertensive drugs are available to treat perioperative hypertension. Labetolol is commonly used to treat hypertension in this situation, but may not be used in certain group of patients because of its low potency, slow onset of peak effect and unpredictability in dose requirements ^[12]. Esmolol is effective to blunt tachycardia but mildly effective in treating perioperative hypertension and its use is further complicated by bradycardia ^[13]. Other drugs like nicardipine, hydralazine are cerebral vasodilator and may increase intracranial pressure and rarely

used in treating hypertension in neurosurgical patients^[14]. In some earlier reports, oral clonidine premedication provided attenuation of the hypertensive response to laryngoscopy and intubation and head holder application in patients undergoing supratentorial surgery^[15]. Dexmedetomidine decreased plasma epinephrine and nor-epinephrine level perioperatively^[16]. Numerous studies in patients undergoing general and gynecological surgery have also shown that dexmedetomidine blunts the cardiovascular responses to intubation^[6,8,9]. So, it was assumed that dexmedetomidine would attenuate hypertensive responses associated with stimulation during anesthesia and surgery. And our study corroborated this assumption. Two studies evaluated its role in patients undergoing intracranial surgery^[2,3]. One study concluded that dexmedetomidine increased perioperative hemodynamic stability in patients undergoing brain tumor surgery and the trachea was extubated faster without respiratory depression^[3].

The gold standard of neuroanesthesia includes maintenance of anesthesia with isoflurane or propofol. Important advantage of propofol in general anesthesia is rapid emergence^[17]. Propofol infusion is usually used for its remarkable safety features but various recent literatures have questioned regarding its prolonged infusion^[18,19,20]. Although majority of such reports have involved its long-term administration in the ICU setting, recent evidence has also suggested the potential for intra operative complications even with short-term infusions^[18,19,20].

In view of the above observations the present study was designed to evaluate the effect of dexmedetomidine on hemodynamics and also requirement of propofol and fentanyl during intra operative period in elective intracranial tumor surgery. It demonstrated that, addition of continuous infusion of dexmedetomidine attenuated the hemodynamic responses at critical moments of anesthesia and surgery as well as during emergence from anesthesia. As a

secondary outcome measure, it also reduced intraoperative propofol and fentanyl requirement. These findings were consistent with studies by Tanskanen P, et al and Scheinin B, et al. where they noted HR attenuation in intubation, but SBP was not attenuated significantly^[3,6]. There were no significant differences between the groups in the HR at extubation. This was on the contrary of our findings. In our study, both HR and Blood Pressure were attenuated also at extubation (significant both statistically and clinically).

Increased risk of bradycardia and hypotension after rapid bolus administration in young healthy volunteers have been reported with dexmedetomidine in general and gynecological surgery^[7,8]. In our study there was no difference in occurrence of bradycardia and hypotension in between groups. HR was better attenuated in dexmedetomidine group at different times which are known for their nociceptive stimulus. No significant difference in SBP, DBP and MAP were found after induction in both group. Significant attenuation of SBP, DBP and MAP occurred at intubation, head pin fixation, incision, making of burr hole, after opening of dura and during extubation (p 0.00) in dexmedetomidine group [Table 3,4,5].

There are some limitations of our study. We selected a constant dexmedetomidine infusion rate of 0.4µg/kg after the initial loading dose of 1µg/kg. As we did not use target controlled infusion, so we selected a midrange dose with common methods of administration. As in normal clinical practice, it is possible that patients who differed in their ability to metabolize this drug received lower or higher effective doses. Factors possibly predictive of this did not differ between the groups. So with a study design in which the anesthesiologist would be permitted to titrate the dexmedetomidine dose, further improvements in hemodynamic stability with shorter awakening times might be demonstrated.

Table-1: Demographic data

Baseline demographic variables	Group D(n=45)	Group C(n=45)	p value
Age (years)	42.36±13.36	38.33±13.13	0.5
Sex (M/F)	22/23	19/26	0.817
Body weight (kg)	57.44±7.7	57.02±7.8	0.797
ASA grade 1 / grade 2	30/15	28/17	0.9
Type of brain tumour			
Meningoma	23	22	0.994
Glioma	16	18	
Astrocytoma	6	5	
Presence of hypertension (yes/no)	12/33	13/32	0.973
Duration of surgery (minutes)	275.82±24.25	275.56±22.63	0.957

Baseline demographics were comparable in both groups. No statistically significant differences seen between the groups.

Table 2: Comparison of Heart rate (beats per minute) at specific time points (mean±standard deviation)

Specific time points	Group D (n=45)	Group C (n=45)	p value
T0	77.31±11.75	79.84±14.22	0.357
T1	69.91±11.11	79.11±14.22	* 0.001
T2	66.96±11.7	78.37±18	*0.00
T3	75.22±15.7	93.97±19	* 0.0001
T4	73.38±14.58	86.97±12.23	* 0.0001
T5	72.18±13.66	85.15±14.89	* 0.0001
T6	71.69±13.57	83.91±13.59	*0.0001
T7	70.8±12.64	82.6±13.73	*0.0001
T8	76.1±12	96.22±15.7	*0.0001

Table 2 shows intraoperative attenuation of heart rate at specific time points mean ±standard deviation. There were statistically significant differences seen between the groups. * denotes statistically significant differences between the

groups. Data were collected at following specific time points: T0 – baseline, T1- after loading dose of drug, T2 – after induction, T3 – intubation, T4 – head pin fixation, T5 – incision, T6 – burr hole, T7 – at opening of dura, T8- after extubation

Table 3. Comparison of Systolic blood pressure (mm Hg) attenuation between Group D and Group C.

Specific time points	Group D (n=45)	Group C (n=45)	p value
T0	127.56±15.48	126.4±15.78	0.721
T1	124.29±16.72	127.66±15.25	0.317
T2	113.53±14.16	108.22±12.25	0.057
T3	115.27±12.14	137.42±16.7	*<0.0001
T4	116.33±12.86	126.84±15	* 0.000
T5	112.36±10.75	122.95±15.7	* 0.000
T6	111.6±13.93	121.82±15	* 0.001
T7	112.78±13.1	125.55±13.71	* < 0.0001
T8	130.91±14.58	149.62±12.8	* < 0.0001

Table 3 shows Intraoperative systolic blood pressure measurements at specific time points mean ±standard deviation. There were statistically significant differences seen between the groups. Data were collected at following specific time points: T0 – baseline, T1- after loading dose of

drug, T2 – after induction, T3 – intubation, T4 – head pin fixation, T5 – incision, T6 – burr hole, T7 – at opening of dura, T8- after extubation. * denotes statistically significant differences between the groups.

Table 4. Comparison of diastolic blood pressure (mm Hg) attenuation between Group D and Group C.

Specific time points	Group D (n=45)	Group C (n=45)	p value
T0	77.44±10.3	77.93±10.5	0.824
T1	72.1±11.11	77.82±10.3	*0.011
T2	67.87±10.15	65.64±8.6	0.263
T3	69±10.09	84.13±11.5	*< 0.0001
T4	71.84±9.72	78.89±9.5	*0.000
T5	71±8.7	80±10.3	*< 0.0001
T6	70.76±9.93	80.16±13.6	*0.000
T7	70.89±11.07	83.84±10.4	* < 0.0001
T8	84.4±8.48	96.62±5.5	*< 0.0001

Table 4 shows Intraoperative diastolic blood pressure measurements at specific time points mean ±standard deviation. There were statistically significant differences seen between the groups. Data were collected at following specific time points: T0 – baseline, T1- after loading dose of drug, T2 – after induction, T3 – intubation, T4 – head pin fixation, T5 – incision, T6 – burr hole, T7 – at opening of dura, T8- after extubation. *

denotes statistically significant differences between the groups.

Table 5. Comparison of mean arterial pressure (mm Hg) in between Group D and Group C.

Specific time points	Group D (n=45)	Group C (n=45)	p value
T0	94.16±10.65	94.16±11.2	1.000
T1	90.44±14.37	95±10	0.093
T2	83.00±10.3	79.91±8.8	0.084
T3	84.44±9.55	101.91±12.2	*< 0.0001
T4	86.64±9.98	95±10.2	*0.001
T5	84.84±8.72	94.38±11.4	*< 0.0001
T6	84.4±10.54	94±13.4	*0.000
T7	84.78±11.25	97.69±10.9	*< 0.0001
T8	99.89±9.61	114.29±6.9	*< 0.0001

Table 5 shows groups. Intraoperative systolic blood pressure measurements at specific time points mean ± standard deviation. There were statistically significant differences seen between the groups. Data were collected at following specific time points: T0 – baseline, T1- after

loading dose of drug, T2 – after induction, T3 – intubation, T4 – head pin fixation, T5 – incision, T6 – burr hole, T7 – at opening of dura, T8- after extubation. * denotes statistically significant differences between the

Table 6. Comparison of Propofol requirement (mL) in both groups.

Requirement of Propofol	Group D (n = 45)	Group C (n = 45)	p value
Induction (mL)	5.62±1.45	10.56±1.4	*< 0.0001
Hourly maintenance (mL)	8.28±1.83	28.12±3.72	*< 0.0001
Total maintenance dose (mL)	41.38±9.16	28.12±3.72	*< 0.0001

Propofol requirement as induction and maintenance agent (both hourly and total requirement) presented and compared here as

mean ± standard deviation in between group D and group C. Statistically significant differences are present as denoted by * in Table no.6 .

Table 7. Comparison of Fentanyl requirement (µg) in both groups.

Requirement of Fentanyl (µg)	Group D (n = 45)	Group C (n = 45)	p value
Hourly requirement	52.76±10.27	93.78±12.5	*< 0.0001
Total requirement	244.33±43.54	448.33±74.89	*< 0.0001

Table 7 shows Fentanyl requirement as induction and maintenance agent (both hourly and total requirement) and data is compared here as mean ±

standard deviation in between group D and group C. Statistically significant differences are present as denoted by *.

Table 8. Adverse events and interventions done in Group D and Group C.

Adverse Events and interventions	Group D (n=45)	Group C (n= 45)	p value
Tachycardia(yes/no)	7/38	28/17	*<0.001
Bradycardia (yes/no)	14/31	12/35	0.897
Hypotension(yes/no)	5/40	4/41	0.940
Intraoperative hypertension (yes/no)	5/40	12/33	0.169
Hypertension at extubation (yes/no)	0/45	5/40	0.071
Use of Labetelol (yes/no)	2/43	12/33	*0.015
Use of Phenylephrine (yes/no)	2/43	4/41	0.700
Use of Esmolol (yes/no)	5/40	26/19	*< 0.0001
Use of Atropine (yes/no)	4/41	3/42	0.925
Intravenous Paracetamol postoperatively (yes/no)	2/43	11/34	*0.026
Post operative nausea and vomiting (yes/no)	0/45	0/45	1.000
Shivering (yes/no)	2/43	9/36	0.07

Table 8 shows adverse intraoperative events and their management in both the groups. Lesser number of patients in Group D suffered from tachycardia than found in Group C ($p < 0.001$). Also intravenous Labetelol use for intraoperative hypertension, intravenous Esmolol administration for tachycardia and postoperative analgesic requirement was found to be lesser in Group D and it was statistically significant ($p < 0.05$).

Incidence of bradycardia, hypotension, intraoperative hypertension, hypertension at extubation, administration of Phenylephrine and Atropine, postoperative nausea and vomiting, and shivering found as having no significant difference between both groups ($p > 0.05$).

*denotes statistically significant p value.




Figure1. Comparison of extubation time in group D and group C.

Mean time for extubation was 16.58 ± 4.9 minutes in group D, and 33.6 ± 7.5 minutes in group C. There was statistically significant difference ($P < 0.0001$).




Figure 2. Comparison of Heart rate (beats per min) attenuation in both groups. Figure 2 shows that mean heart rate attenuation was better in Group D.




Figure 3. Comparison of trend during intraoperative systolic, diastolic and mean blood pressure between both groups.

Figure 3 compares the trend of Systolic, Diastolic and Mean blood pressure of Group D and Group

C. Descriptive data of Group D was found to have better attenuation in the above figure.




Figure 4. Comparison of Propofol and Fentanyl requirement between Group D and Group C.

Figure 4 showing and comparing the requirement of Propofol and Fentanyl between the groups. Data are presented here as mean.

Conclusion

In conclusion, a continuous infusion of dexmedetomidine maintained hemodynamic stability better than placebo in patients undergoing intracranial surgery without increasing the incidence of hypotensive episodes or bradycardia. It also reduced the intraoperative propofol and fentanyl requirement. In addition, patients treated with dexmedetomidine were extubated earlier and required less analgesic in the immediate postoperative period than the control group.

Acknowledgement: Nil.

References

1. Basali A, Mascha EJ, Kalfas I, Schubert A. Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. *Anesthesiology* 2000; 93:48-54.
2. Gunes Y, Gunduz M, Ozcengiz D, Ozbek H, Isik G. Dexmedetomidine-remifentanyl or propofol-remifentanyl anesthesia in patients undergoing intracranial surgery. *Neurosurg Q* 2005; 15: 122-6.
3. Tanskanen P, Kytta J, Randell T, Aantaa R. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumor surgery: a double-blind, randomized and placebo-controlled study. *Br J Anaesth* 2006;97: 658-65.
4. Hall JE, Uhrich TD, Barney JA, Shahbaz RA, Ebert TJ. Sedative, amnestic, and analgesic properties of small dose dexmedetomidine infusions. *Anesth Analg* 2000; 90: 699-705.
5. Bekker A, Sturaitis M. Dexmedetomidine for neurological surgery. *Neurosurgery* 2005; 57: 1-10.
6. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. *Br J Anaesth* 1992; 68: 126-31.
7. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. *Anesthesiology* 1992; 77: 1125-33.

8. Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. *Anesth Analg* 1992; 75: 940-6.
9. Aantaa R, Jaakola ML, Kallio A, Kanto J. Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. *Anesthesiology* 1997; 86: 1055-60.
10. Kallio A, Scheinin M, Koulu M, et al. Effects of dexmedetomidine, a selective alpha 2- adrenoceptor agonist, on hemodynamic control mechanisms. *Clin Pharmacol Ther* 1989; 46: 33-42.
11. Olsen K, Pedersen C, Madsen J, Ravn L, Schifter S. Vasoactive modulators during and after craniotomy: relation to postoperative hypertension. *J Neurosurg Anesth* 2002; 14: 171-9.
12. Kross R, Ferri E, Leung D, Pratala M, Broad C, Veronesi M, Melendez J. A comparative study between a calcium channel blocker (nicardipine) and combined α - β -blocker (labetelol) for the control of emergence hypertension during craniotomy for tumor surgery. *Anesth Analg* 2000; 91: 904-9.
13. Haas C, LeBlac J. Acute postoperative hypertension: a review of therapeutic options. *Am J Health- Syst Pharm* 2004; 61: 1661-73.
14. Akopov S, Simonian N, Kazarian A. Effects of nifedipine and Nicardipine on regional cerebral blood flow distribution in patients with arterial hypertension. *Methods Find Exp Clin Pharmac* 1996; 18: 685-92.
15. Chadha R, Padmanabhan V, Joseph A, Mohandas K. Oral clonidine pretreatment for hemodynamic stability during craniotomy. *Anaesth Intensive Care* 1992; 20: 341-4.
16. Bekker A, Basile J, Gold M, Riles T, Adelman M, Cuff G, Mathew J, Goldberg J. Dexmedetomidine for awake carotid carotid Endarterectomy: efficacy, hemodynamic profile, and side effects. *J Neurosurg Anesth* 2004; 16: 126-35.
17. Marshall CA, Jones RM, Bajorek PK, Cashman JN. Recovery characteristics using isoflurane or propofol for maintenance of anaesthesia: a double-blind controlled trial. *Anaesthesia* 1992; 47: 461-6.
18. Burow, BK. Johnson ME. Packer DL. Metabolic Acidosis Associated with Propofol in the Absence of Other Causative Factors. Case report. *Anesthesiology* 2004; 101:239-41.
19. Salengros JC, Velghe-Lenelle CE, Bollens R, Engelman E, Barvais L. Lactic Acidosis during Propofol-Remifentanyl Anaesthesia in an Adult. Case report. *Anesthesiology* 2004; 101:241-3.
20. Hatch DJ. Propofol infusion syndrome in children. *Lancet* 1999; 353: 1117-18.